Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours

Next Previous
Search
Trial Profile

Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Datopotamab deruxtecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms TROPION-PanTumor02
  • Sponsors AstraZeneca

    • Most Recent Events

    • 23 Sep 2024 Planned End Date changed from 6 May 2024 to 30 Dec 2024.
    • 04 Jun 2024 Results from the NSCLC cohort presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 22 May 2024 According to an AstraZeneca media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top